Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|July 23, 2018
ROTEM Can Predict Thrombotic Events in Rheumatoid Arthritis
Although disease activity remains the key risk factor, this test can identify a greater predisposition to thrombosis.
Advertisement
Reference1. Türk SM, Cansu DÃ, Teke HÃ, et al. Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM). Clin Rheumatol. 2018 May 7. doi: 10.1007/s10067-018-4134-y. [Epub ahead of print]
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement